TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TeleCare Management of Pain and Depression in Cancer
Brief Summary: RATIONALE: Telemedicine may help in the treatment of depression and/or pain caused by cancer. It is not yet known whether telemedicine is more effective than standard care in treating depression and/or pain caused by cancer.

PURPOSE: This phase III randomized clinical trial is studying telemedicine to see how well it works compared to standard care in treating patients with depression and/or pain caused by cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
C: Arm Label: Assistance with Pain Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Assistance with Pain treatment | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Assistance with Pain treatment; Assigned to Arm(s): Assistance with Pain Treatment
D: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TeleCare Management of Pain and Depression in Cancer
Brief Summary: RATIONALE: Telemedicine may help in the treatment of depression and/or pain caused by cancer. It is not yet known whether telemedicine is more effective than standard care in treating depression and/or pain caused by cancer.

PURPOSE: This phase III randomized clinical trial is studying telemedicine to see how well it works compared to standard care in treating patients with depression and/or pain caused by cancer.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Psycho-educational intervention | Intervention Type: OTHER; Name: Psycho-educational intervention; Assigned to Arm(s): Intervention
B: Arm Label: German PRO-SELF(c) Plus PCP; Type: EXPERIMENTAL; Interventions: Behavioral: German PRO-SELF(c) Plus Pain Control Program (PCP) | Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: German PRO-SELF(c) Plus Pain Control Program (PCP), Other: Standard Care | Intervention Type: BEHAVIORAL; Name: German PRO-SELF(c) Plus Pain Control Program (PCP); Assigned to Arm(s): German PRO-SELF(c) Plus PCP, Standard Care | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: Telephone counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone counseling | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Telephone counseling; Assigned to Arm(s): Telephone counseling | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education
D: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Brief Summary: The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.


Options:
A: Arm Label: RBCT based on rSO2 value; Type: EXPERIMENTAL; Interventions: Procedure: Red blood cells transfusion | Arm Label: RBCT based on hemoglobin level value; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Red blood cells transfusion | Intervention Type: PROCEDURE; Name: Red blood cells transfusion; Assigned to Arm(s): RBCT based on hemoglobin level value, RBCT based on rSO2 value
B: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
C: Arm Label: Appropriate transfusion policy; Type: N/A; Interventions: N/A | Arm Label: Non-Appropriate transfusion policy; Type: N/A; Interventions: N/A
D: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Brief Summary: The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.


Options:
A: Arm Label: bCBT/Direct Referral; Type: EXPERIMENTAL; Interventions: Behavioral: bCBT | Arm Label: Enhanced Usual Care (EUC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: bCBT; Assigned to Arm(s): bCBT/Direct Referral
B: Arm Label: Biological; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Arm Label: Standard PRBCs; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Intervention Type: BIOLOGICAL; Name: Transfusion; Assigned to Arm(s): Biological, Standard PRBCs
C: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of 5 days or less storage age | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: RBC transfusion of conventional storage age | Intervention Type: OTHER; Name: RBC transfusion of 5 days or less storage age; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: RBC transfusion of conventional storage age; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Brief Summary: The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.


Options:
A: Arm Label: Restrictive Red blood cell Transfusion; Type: EXPERIMENTAL; Interventions: Other: Red blood cell Transfusion | Arm Label: Liberal Red blood Cell Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell Transfusion | Intervention Type: OTHER; Name: Red blood cell Transfusion; Assigned to Arm(s): Liberal Red blood Cell Transfusion, Restrictive Red blood cell Transfusion
B: Arm Label: Liberal Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive transfusion strategy; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive transfusion strategy
C: Arm Label: Low transfusion threshold; Type: EXPERIMENTAL; Interventions: Biological: Red blood cell transfusion | Arm Label: High transfusion threshold; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): High transfusion threshold, Low transfusion threshold
D: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Brief Summary: The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.


Options:
A: Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Erythropoietin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
D: Arm Label: EPO group; Type: EXPERIMENTAL; Interventions: Drug: EPO group | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: EPO group; Assigned to Arm(s): EPO group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury
Brief Summary: The purpose of this study is to determine the effect of early administration of recombinant human erythropoietin on long-term neurological outcome after severe traumatic brain injury.


Options:
A: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
B: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
C: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
D: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Back-to Back Trial of Narrow Band Imaging (NBI) With Magnification Versus Standard Colonoscopy for Colonic Neoplasia Surveillance in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients
Brief Summary: The purpose of this study is to determine whether a new colonoscopic viewing technique called narrow band imaging (NBI)can help doctors detect more patients with at least one pre-cancerous area than conventional colonoscopy using white light alone in patients with genetically inherited high risk for bowel cancer (HNPCC).


Options:
A: Arm Label: Narrow band imaging colonoscope; Type: EXPERIMENTAL; Interventions: Device: Narrow band imaging colonoscope | Arm Label: White Light; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Narrow band imaging colonoscope; Assigned to Arm(s): Narrow band imaging colonoscope
B: Arm Label: colonoscopy; Type: EXPERIMENTAL; Interventions: Device: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test) | Intervention Type: DEVICE; Name: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test); Assigned to Arm(s): colonoscopy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: standard of care colonoscopy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: standard of care colonoscopy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Procedure: colonoscopy | Intervention Type: PROCEDURE; Name: standard of care colonoscopy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: colonoscopy; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: standard of care colonoscopy; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: Narrow Band Imaging; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 13-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin (150-600 Mg/Day) Using A Flexible Dosing Schedule In The Treatment Of Subjects With Central Post-Stroke Pain (CPSP)
Brief Summary: Efficacy and Safety of flexibly dosed pregabalin compared to placebo among subjects with central post stroke pain (CPSP)


Options:
A: Arm Label: Lyrica (pregabalin); Type: EXPERIMENTAL; Interventions: Drug: Lyrica (pregabalin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lyrica (pregabalin); Assigned to Arm(s): Lyrica (pregabalin) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Imipramine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipramine | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Imipramine plus pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Imipramine, pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Imipramine; Assigned to Arm(s): Imipramine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Imipramine, pregabalin; Assigned to Arm(s): Imipramine plus pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Pregabain; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabain | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Large Scale Safety Study of a DTaP-IPV-Hep B-PRP~T Combined Vaccine, in Comparison to Tritanrix-Hep B/Hib™ and OPV Administered at 2, 4, and 6 Months of Age in Latin American Infants
Brief Summary: To demonstrate that DTaP-IPV-HB-PRP\~T combined vaccine does not induce a higher incidence rate of high fever than Tritanrix-HepB/Hib™ and Oral Polio Vaccine (OPV) after any of the three vaccinations at 2, 4, and 6 months of age for each subject.

To evaluate the overall safety in terms of:

Any solicited adverse reactions in the first 7 days after each injection, Any adverse events and reactions in the first 30 days after each injection, Any serious adverse events during the trial.

Immunogenicity:

To document the immune response to Hepatitis B antigen of the three batches of the investigational DTaP-IPV-HB-PRP\~T vaccine.


Options:
A: Arm Label: Phase A - SI; Type: EXPERIMENTAL; Interventions: Biological: Bordetella Pertussis B1917, Drug: Azithromycin 500 mg | Arm Label: Phase B Inoculum; Type: EXPERIMENTAL; Interventions: Biological: Bordetella Pertussis B1917, Drug: Azithromycin 500 mg | Arm Label: Phase B Sham; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin 500 mg, Other: Sterile Saline | Intervention Type: BIOLOGICAL; Name: Bordetella Pertussis B1917; Assigned to Arm(s): Phase A - SI, Phase B Inoculum | Intervention Type: DRUG; Name: Azithromycin 500 mg; Assigned to Arm(s): Phase A - SI, Phase B Inoculum, Phase B Sham | Intervention Type: OTHER; Name: Sterile Saline; Assigned to Arm(s): Phase B Sham
B: Arm Label: Allergy Cases; Type: N/A; Interventions: N/A | Arm Label: Controls; Type: N/A; Interventions: N/A
C: Arm Label: Group 1: DTaP-IPV-Hep B-PRP-T; Type: EXPERIMENTAL; Interventions: Biological: DTaP-IPV-HB-PRP~T | Arm Label: Group 2: Tritanrix-Hep B/Hib™+OPV; Type: ACTIVE_COMPARATOR; Interventions: Biological: Tritanrix-HepB/Hib | Intervention Type: BIOLOGICAL; Name: DTaP-IPV-HB-PRP~T; Assigned to Arm(s): Group 1: DTaP-IPV-Hep B-PRP-T | Intervention Type: BIOLOGICAL; Name: Tritanrix-HepB/Hib; Assigned to Arm(s): Group 2: Tritanrix-Hep B/Hib™+OPV
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Biological: Boostrix, Biological: Infanrix hexa | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Boostrix, Biological: Quinvaxem, Biological: OPV | Intervention Type: BIOLOGICAL; Name: Boostrix; Assigned to Arm(s): Group A, Group B | Intervention Type: BIOLOGICAL; Name: Infanrix hexa; Assigned to Arm(s): Group A | Intervention Type: BIOLOGICAL; Name: Quinvaxem; Assigned to Arm(s): Group B | Intervention Type: BIOLOGICAL; Name: OPV; Assigned to Arm(s): Group B

Answer: C